Editorial
Igor Klepikov
Abstract
This message is intended primarily for specialists in the field of acute inflammatory lung diseases who are familiar with the problems of treatment of acute pneumonia (ÐÂÂÐ ) today and who do not need to provide a review of the literature on this topic. That is why, the title of this letter, I have almost no doubt, will cause many readers at least extreme bewilderment. And such bewilderment in the light of the current situation in this field of medicine at first glance will be quite reasonable and logical. Indeed, what savings in the treatment of AP can be said if, according to the World Health Organization, the existing treatment potential is already extremely insufficient” Pneumonia caused by bacteria can be treated with antibiotics, but only one third of children with pneumonia receive the antibiotics they need”. And it is known that “Pneumonia accounts for 16% of all deaths of children under 5 years old, killing 920 136 children in 2015”